Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert N Schuck

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Clinical Pharmacology and Therapeutics|July 19, 2021
Evidence, in Context: A Regulatory Perspective on PharmacogeneticsMichael Pacanowski, Robert N Schuck
Clinical and Translational Science|October 2, 2025
Use of Biomarkers in Drug Development for Regulatory PurposesRobert N Schuck, Vanitha Sekar
The AAPS Journal|February 26, 2016
Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product LabelingRobert N Schuck, Joseph A Grillo
Pharmacogenomics|April 20, 2022
Premarket assessment of molecular alterations in drug targets: a case study of 2020 drug approvalsOluseyi Adeniyi, Mary Hwang, Jielin Sun, et al.
Pharmacotherapy|April 23, 2013
Beyond statins: lipid management to reduce cardiovascular riskRobert N Schuck, Philip M Mendys, Ross J Simpson
Nature Reviews. Drug Discovery|December 23, 2017
Regulatory policy for the development of targeted therapies for low-frequency molecular subtypes of diseaseRobert N Schuck, Michael Pacanowski, Janet Woodcock, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 20, 2016
Clinical and regulatory considerations in pharmacogenetic testingRobert N Schuck, Elizabeth Marek, Hobart Rogers, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 3, 2024
Leveraging in Vitro Models for Clinically Relevant Rare <i>CYP2D6</i> Variants in PharmacogenomicsSydney Stern, Paula L Hyland, Michael Pacanowski, et al.
Clinical and Translational Science|February 22, 2019
Use of Titration as a Therapeutic Individualization Strategy: An Analysis of Food and Drug Administration-Approved DrugsRobert N Schuck, Michael Pacanowski, Sarah Kim, et al.
Nature Reviews. Drug Discovery|February 26, 2026
Dose-finding and optimization in drug development for rare diseasesRobert N Schuck, Ruo-Jing Li, Mia Williams, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology and Therapeutics|July 19, 2021
Evidence, in Context: A Regulatory Perspective on PharmacogeneticsMichael Pacanowski, Robert N Schuck
Clinical and Translational Science|October 2, 2025
Use of Biomarkers in Drug Development for Regulatory PurposesRobert N Schuck, Vanitha Sekar
The AAPS Journal|February 26, 2016
Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product LabelingRobert N Schuck, Joseph A Grillo
Pharmacogenomics|April 20, 2022
Premarket assessment of molecular alterations in drug targets: a case study of 2020 drug approvalsOluseyi Adeniyi, Mary Hwang, Jielin Sun, et al.
Pharmacotherapy|April 23, 2013
Beyond statins: lipid management to reduce cardiovascular riskRobert N Schuck, Philip M Mendys, Ross J Simpson
Nature Reviews. Drug Discovery|December 23, 2017
Regulatory policy for the development of targeted therapies for low-frequency molecular subtypes of diseaseRobert N Schuck, Michael Pacanowski, Janet Woodcock, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 20, 2016
Clinical and regulatory considerations in pharmacogenetic testingRobert N Schuck, Elizabeth Marek, Hobart Rogers, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 3, 2024
Leveraging in Vitro Models for Clinically Relevant Rare <i>CYP2D6</i> Variants in PharmacogenomicsSydney Stern, Paula L Hyland, Michael Pacanowski, et al.
Clinical and Translational Science|February 22, 2019
Use of Titration as a Therapeutic Individualization Strategy: An Analysis of Food and Drug Administration-Approved DrugsRobert N Schuck, Michael Pacanowski, Sarah Kim, et al.
Nature Reviews. Drug Discovery|February 26, 2026
Dose-finding and optimization in drug development for rare diseasesRobert N Schuck, Ruo-Jing Li, Mia Williams, et al.
Pageof 3